Restoration of Lactobacillus johnsonii and Enterococcus faecalis Caused the Elimination of Tritrichomonas sp. in a Model of Antibiotic-Induced Dysbiosis
- PMID: 38791132
- PMCID: PMC11120941
- DOI: 10.3390/ijms25105090
Restoration of Lactobacillus johnsonii and Enterococcus faecalis Caused the Elimination of Tritrichomonas sp. in a Model of Antibiotic-Induced Dysbiosis
Abstract
Inflammatory bowel disease (IBD) is a multifactorial disease involving the interaction of the gut microbiota, genes, host immunity, and environmental factors. Dysbiosis in IBD is associated with pathobiont proliferation, so targeted antibiotic therapy is a rational strategy. When restoring the microbiota with probiotics, it is necessary to take into account the mutual influence of co-cultivated microorganisms, as the microbiota is a dynamic community of species that mediates homeostasis and physiological processes in the intestine. The aim of our study was to investigate the recovery efficacy of two potential probiotic bacteria, L. johnsonii and E. faecalis, in Muc2-/- mice with impaired mucosal layer. Two approaches were used to determine the efficacy of probiotic supplementation in mice with dysbiosis caused by mucin-2 deficiency: bacterial seeding on selective media and real-time PCR analysis. The recovery time and the type of probiotic bacteria relocated affected only the number of E. faecalis. A significant positive correlation was found between colony-forming unit (CFU) and the amount of E. faecalis DNA in the group that was replanted with probiotic E. faecalis. As for L. johnsonii, it could be restored to its original level even without any additional bacteria supplementation after two weeks. Interestingly, the treatment of mice with L. johnsonii caused a decrease in the amount of E. faecalis. Furthermore, either L. johnsonii or E. faecalis treatment eliminated protozoan overgrowth caused by antibiotic administration.
Keywords: IBD; antibiotic treatment; bacteria recovery; microbiota; protozoa.
Conflict of interest statement
The authors declare no conflicts of interest.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11120941/bin/ijms-25-05090-g001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11120941/bin/ijms-25-05090-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11120941/bin/ijms-25-05090-g003.gif)
Similar articles
-
Intranasal administration of Lactobacillus johnsonii attenuates hyperoxia-induced lung injury by modulating gut microbiota in neonatal mice.J Biomed Sci. 2023 Jul 31;30(1):57. doi: 10.1186/s12929-023-00958-8. J Biomed Sci. 2023. PMID: 37517995 Free PMC article.
-
Lactobacillus johnsonii YH1136 plays a protective role against endogenous pathogenic bacteria induced intestinal dysfunction by reconstructing gut microbiota in mice exposed at high altitude.Front Immunol. 2022 Oct 10;13:1007737. doi: 10.3389/fimmu.2022.1007737. eCollection 2022. Front Immunol. 2022. PMID: 36304467 Free PMC article.
-
Role of Mucin 2 Glycoprotein and L-Fucose in Interaction of Immunity and Microbiome within the Experimental Model of Inflammatory Bowel Disease.Biochemistry (Mosc). 2022 Apr;87(4):301-318. doi: 10.1134/S0006297922040010. Biochemistry (Mosc). 2022. PMID: 35527372
-
Links Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease.Front Immunol. 2020 Sep 11;11:2144. doi: 10.3389/fimmu.2020.02144. eCollection 2020. Front Immunol. 2020. PMID: 33042125 Free PMC article. Review.
-
Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.J Microbiol. 2018 Mar;56(3):189-198. doi: 10.1007/s12275-018-8049-8. Epub 2018 Feb 28. J Microbiol. 2018. PMID: 29492876 Review.
References
-
- Nelson C., Clarizio K., Elkattah R. The Tricky Trichomonas: A Tale of Resistance. Am. J. Obstet. Gynecol. 2019;221:695. doi: 10.1016/j.ajog.2019.10.062. - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous